The Ki67 antigen is a prototypic cell cycle-related protein expressed by proliferating cells in all phases of the active cell cycle (G1, S, G2 and M). It is a non-histone nuclear protein originally identified in a Hodgkin's lymphoma-derived cell line. Ki67 interacts with KIF15 and MKI67IP, and is approximately 395 kD. It exhibits a complex nuclear localization pattern that is cell cycle-dependent - expression peaks during late G1, S, G2, and M phases, but is undetectable in G0. Ki67 is phosphorylated and dephosphorylated during mitosis, and appears to be susceptible to proteolytic regulation. Due to its cell cycle association, Ki67 is routinely used as cell cycling and proliferation marker. Additionally, Ki67 antibodies are useful in establishing the cell growing fraction in solid tumors and certain hematological malignancies.
Original immunobiochemical characterization of the Ki67 antibody validated its exclusive expression in proliferating, but not quiescent, cell cohorts1. Molecular labeling studies from Zambon‘s lab at UCSD introduced a novel and dynamic real-time visualization cell cycle entry detection method with the Ki67 antibody2. This genetic-based reporter method can be done with live cells in intact complex 3D cellular aggregates and has unique advantages over conventional methods. Swartling’s group used the Ki67 antibody to profile the role of MYCN in malignant childhood medulloblastoma (MB) and found that it has a wide reaching and pleiotropic role in the initiation, progression, and maintenance of the tumor3. Jakate et al from the University of Toronto undertook a comprehensive and intricately detailed classification of endometrial sarcomas with regards to morphology, immunohistochemistry, and cytogenetics. Their study required immunohistochemistry with the Ki67 antibody and they concluded that there are distinct profiles indicative of the undifferentiated versus low-grade sarcomas4. Recently, He’s group used the Ki67 antibody in immunoblotting to assess the efficacy of folate-linked lipoplexes targeting claudin3 (CLDN3) in ovarian cancer gene therapy5. Novus Biologicals offers Ki67 reagents for your research needs including:
PMIDs
